Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 237

1.

Phyllodes tumours of the breast: a consensus review.

Tan BY, Acs G, Apple SK, Badve S, Bleiweiss IJ, Brogi E, Calvo JP, Dabbs DJ, Ellis IO, Eusebi V, Farshid G, Fox SB, Ichihara S, Lakhani SR, Rakha EA, Reis-Filho JS, Richardson AL, Sahin A, Schmitt FC, Schnitt SJ, Siziopikou KP, Soares FA, Tse GM, Vincent-Salomon A, Tan PH.

Histopathology. 2016 Jan;68(1):5-21. doi: 10.1111/his.12876. Review.

2.

Menopausal status does not predict Oncotype DX recurrence score.

Carr DN, Vera N, Sun W, Lee MC, Hoover S, Fulp W, Acs G, Laronga C.

J Surg Res. 2015 Sep;198(1):27-33. doi: 10.1016/j.jss.2015.05.034. Epub 2015 Jun 12.

PMID:
26095420
3.
4.

Interobserver variability by pathologists in the distinction between cellular fibroadenomas and phyllodes tumors.

Lawton TJ, Acs G, Argani P, Farshid G, Gilcrease M, Goldstein N, Koerner F, Rowe JJ, Sanders M, Shah SS, Reynolds C.

Int J Surg Pathol. 2014 Dec;22(8):695-8. doi: 10.1177/1066896914548763. Epub 2014 Aug 26.

5.

Surgical excision of pure flat epithelial atypia identified on core needle breast biopsy.

Prowler VL, Joh JE, Acs G, Kiluk JV, Laronga C, Khakpour N, Lee MC.

Breast. 2014 Aug;23(4):352-6. doi: 10.1016/j.breast.2014.01.013. Epub 2014 Feb 8.

6.

Comparison of Oncotype DX and Mammostrat risk estimations and correlations with histologic tumor features in low-grade, estrogen receptor-positive invasive breast carcinomas.

Acs G, Kiluk J, Loftus L, Laronga C.

Mod Pathol. 2013 Nov;26(11):1451-60. doi: 10.1038/modpathol.2013.88. Epub 2013 Jun 7.

7.

Lymphatic invasion predicts aggressive behavior in melanocytic tumors of uncertain malignant potential (MELTUMP).

Abraham RM, Karakousis G, Acs G, Ziober AF, Cerroni L, Mihm MC Jr, Elder DE, Xu X.

Am J Surg Pathol. 2013 May;37(5):669-75. doi: 10.1097/PAS.0b013e318288ff47.

8.

Melanocytic tumors express connexin 43 but not 26: immunohistochemical analysis with potential significance in melanocytic oncogenesis.

Sargen MR, Gormley RH, Pasha TL, Yum S, Acs G, Xu X, Zhang PJ.

Am J Dermatopathol. 2013 Dec;35(8):813-7. doi: 10.1097/DAD.0b013e318278d401.

PMID:
23344009
9.

Breast preservation in women with giant juvenile fibroadenoma.

Matz D, Kerivan L, Reintgen M, Akman K, Lozicki A, Causey T, Clynes C, Giuliano R, Acs G, Cox J, Cox C, Reintgen D.

Clin Breast Cancer. 2013 Jun;13(3):219-22. doi: 10.1016/j.clbc.2012.10.003. Epub 2012 Dec 14. No abstract available.

PMID:
23245878
10.

Treatment Choices Based on OncotypeDx in the Breast Oncology Care Setting.

Malo TL, Lipkus I, Wilson T, Han HS, Acs G, Vadaparampil ST.

J Cancer Epidemiol. 2012;2012:941495. doi: 10.1155/2012/941495. Epub 2012 Aug 13.

11.

The impact of the size of nodal metastases on recurrence risk in breast cancer patients with 1-3 positive axillary nodes after mastectomy.

Harris EE, Freilich J, Lin HY, Chuong M, Acs G.

Int J Radiat Oncol Biol Phys. 2013 Mar 1;85(3):609-14. doi: 10.1016/j.ijrobp.2012.05.050. Epub 2012 Aug 3.

PMID:
22867892
12.

The diagnosis of endometrial carcinomas with clear cells by gynecologic pathologists: an assessment of interobserver variability and associated morphologic features.

Fadare O, Parkash V, Dupont WD, Acs G, Atkins KA, Irving JA, Pirog EC, Quade BJ, Quddus MR, Rabban JT 3rd, Vang R, Hecht JL.

Am J Surg Pathol. 2012 Aug;36(8):1107-18. doi: 10.1097/PAS.0b013e31825dd4b3. Erratum in: Am J Surg Pathol. 2013 Mar;37(3):458.

PMID:
22790851
13.
14.

The extent of retraction clefts correlates with lymphatic vessel density and VEGF-C expression and predicts nodal metastasis and poor prognosis in early-stage breast carcinoma.

Acs G, Paragh G, Rakosy Z, Laronga C, Zhang PJ.

Mod Pathol. 2012 Feb;25(2):163-77. doi: 10.1038/modpathol.2011.138. Epub 2011 Oct 21.

15.

The effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists.

Joh JE, Esposito NN, Kiluk JV, Laronga C, Lee MC, Loftus L, Soliman H, Boughey JC, Reynolds C, Lawton TJ, Acs PI, Gordan L, Acs G.

Oncologist. 2011;16(11):1520-6. doi: 10.1634/theoncologist.2011-0045. Epub 2011 Oct 20.

16.

Erythropoietin receptor contributes to melanoma cell survival in vivo.

Kumar SM, Zhang G, Bastian BC, Arcasoy MO, Karande P, Pushparajan A, Acs G, Xu X.

Oncogene. 2012 Mar 29;31(13):1649-60. doi: 10.1038/onc.2011.366. Epub 2011 Aug 22.

17.

Connexin 43 is a potential prognostic biomarker for ewing sarcoma/primitive neuroectodermal tumor.

Bui MM, Han G, Acs G, Reed D, Gonzalez RJ, Pasha TL, Zhang PJ.

Sarcoma. 2011;2011:971050. doi: 10.1155/2011/971050. Epub 2011 May 8.

18.

Expression of erythropoietin and its receptor increases in colonic neoplastic progression: the role of hypoxia in tumorigenesis.

Gombos Z, Danihel L, Repiska V, Acs G, Furth E.

Indian J Pathol Microbiol. 2011 Apr-Jun;54(2):273-8. doi: 10.4103/0377-4929.81591.

19.

Invasive ductal carcinomas of the breast showing partial reversed cell polarity are associated with lymphatic tumor spread and may represent part of a spectrum of invasive micropapillary carcinoma.

Acs G, Esposito NN, Rakosy Z, Laronga C, Zhang PJ.

Am J Surg Pathol. 2010 Nov;34(11):1637-46. doi: 10.1097/PAS.0b013e3181f5539c.

PMID:
20975342
20.

Gene expression profiling in breast cancer.

Turaga K, Acs G, Laronga C.

Cancer Control. 2010 Jul;17(3):177-82. Review.

PMID:
20664515
21.

Adenoid cystic carcinoma of the breast: a review of a single institution's experience.

Sarnaik AA, Meade T, King J, Acs G, Hoover S, Cox CE, Carter WB, Laronga C.

Breast J. 2010 Mar-Apr;16(2):208-10. doi: 10.1111/j.1524-4741.2009.00876.x. Epub 2009 Dec 16. Review. No abstract available.

PMID:
20030648
22.

RNA interference-mediated inhibition of erythropoietin receptor expression suppresses tumor growth and invasiveness in A2780 human ovarian carcinoma cells.

Paragh G, Kumar SM, Rakosy Z, Choi SC, Xu X, Acs G.

Am J Pathol. 2009 Apr;174(4):1504-14. doi: 10.2353/ajpath.2009.080592. Epub 2009 Mar 5.

23.
24.

The presence of micropapillary features and retraction artifact in core needle biopsy material predicts lymph node metastasis in breast carcinoma.

Acs G, Paragh G, Chuang ST, Laronga C, Zhang PJ.

Am J Surg Pathol. 2009 Feb;33(2):202-10. doi: 10.1097/PAS.0b013e318185e171.

PMID:
18987549
25.

Cytoplasmic overexpression of WT-1 in gastrointestinal stromal tumor and other soft tissue tumors.

Bing Z, Pasha TL, Acs G, Zhang PJ.

Appl Immunohistochem Mol Morphol. 2008 Jul;16(4):316-21. doi: 10.1097/PAI.0b013e31815c2e02.

PMID:
18528287
26.

Lymphatic invasion revealed by multispectral imaging is common in primary melanomas and associates with prognosis.

Xu X, Gimotty PA, Guerry D, Karakousis G, Van Belle P, Liang H, Montone K, Pasha T, Ming ME, Acs G, Feldman M, Barth S, Hammond R, Elenitsas R, Zhang PJ, Elder DE.

Hum Pathol. 2008 Jun;39(6):901-9. doi: 10.1016/j.humpath.2007.10.017. Epub 2008 Apr 28.

27.

High-risk benign breast lesions: current strategies in management.

Kiluk JV, Acs G, Hoover SJ.

Cancer Control. 2007 Oct;14(4):321-9. Review.

PMID:
17914332
28.

Spleen autotransplantation. Morphological and functional follow-up after spleen autotransplantation in mice: a research summary.

Miko I, Brath E, Nemeth N, Furka A, Sipka S Jr, Peto K, Serfozo J, Kovacs J, Imre S, Benko I, Galuska L, Sipka S, Acs G, Furka I.

Microsurgery. 2007;27(4):312-6. Review.

PMID:
17477433
29.

Survival and invasiveness of astrocytomas promoted by erythropoietin.

Mohyeldin A, Dalgard CL, Lu H, Mcfate T, Tait AS, Patel VC, Wong K, Rushing E, Roy S, Acs G, Verma A.

J Neurosurg. 2007 Feb;106(2):338-50.

PMID:
17410721
30.

Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma.

Kumar SM, Yu H, Edwards R, Chen L, Kazianis S, Brafford P, Acs G, Herlyn M, Xu X.

Cancer Res. 2007 Apr 1;67(7):3177-84.

31.

Nuclear orphan receptor TR3/Nur77 mediates melanoma cell apoptosis.

Yu H, Kumar SM, Fang D, Acs G, Xu X.

Cancer Biol Ther. 2007 Mar;6(3):405-12. Epub 2007 Mar 28.

PMID:
17297306
32.

Podoplanin is a highly sensitive and specific marker to distinguish primary skin adnexal carcinomas from adenocarcinomas metastatic to skin.

Liang H, Wu H, Giorgadze TA, Sariya D, Bellucci KS, Veerappan R, Liegl B, Acs G, Elenitsas R, Shukla S, Youngberg GA, Coogan PS, Pasha T, Zhang PJ, Xu X.

Am J Surg Pathol. 2007 Feb;31(2):304-10.

PMID:
17255777
33.

Extensive retraction artifact correlates with lymphatic invasion and nodal metastasis and predicts poor outcome in early stage breast carcinoma.

Acs G, Dumoff KL, Solin LJ, Pasha T, Xu X, Zhang PJ.

Am J Surg Pathol. 2007 Jan;31(1):129-40.

PMID:
17197929
34.

Immunoprofile of endocervical and endometrial stromal cells and its potential application in localization of tumor involvement.

Barroeta JE, Pasha TL, Acs G, Zhang PJ.

Int J Gynecol Pathol. 2007 Jan;26(1):76-82.

PMID:
17197901
35.

Can Melan-A replace S-100 and HMB-45 in the evaluation of sentinel lymph nodes from patients with malignant melanoma?

Kucher C, Zhang PJ, Acs G, Roberts S, Xu X.

Appl Immunohistochem Mol Morphol. 2006 Sep;14(3):324-7.

PMID:
16932024
36.

Erythropoietin receptors on cancer cells: exciting perspectives, difficult to appreciate.

Henke M, Verma A, Acs G.

Blood. 2006 Aug 1;108(3):1107-8; author reply 1108-9. No abstract available.

PMID:
16861357
37.

Erythropoietin activates the phosphoinositide 3-kinase/Akt pathway in human melanoma cells.

Kumar SM, Yu H, Fong D, Acs G, Xu X.

Melanoma Res. 2006 Aug;16(4):275-83.

PMID:
16845323
38.

Isolation of a novel population of multipotent adult stem cells from human hair follicles.

Yu H, Fang D, Kumar SM, Li L, Nguyen TK, Acs G, Herlyn M, Xu X.

Am J Pathol. 2006 Jun;168(6):1879-88.

39.

Repeat operative sentinel lymph node biopsy.

Jackson BM, Kim S, Davidson R, Schuchter L, Acs G, Czerniecki BJ.

Clin Breast Cancer. 2006 Feb;6(6):530-2.

PMID:
16595037
41.

[Effect of the introduction of quality control on the working standards of specialist outpatient clinics].

Záborszky Z, Acs G, Papp T, Balatoni I, Fekete K.

Orv Hetil. 2006 Feb 5;147(5):229-31. Hungarian.

PMID:
16509224
42.
43.

Serous and mucinous borderline (low malignant potential) tumors of the ovary.

Acs G.

Am J Clin Pathol. 2005 Jun;123 Suppl:S13-57. Review.

PMID:
16100867
44.

Erythropoietin receptor function and expression in epithelial ovarian carcinoma.

McBroom JW, Acs G, Rose GS, Krivak TC, Mohyeldin A, Verma A.

Gynecol Oncol. 2005 Dec;99(3):571-7. Epub 2005 Jul 26.

PMID:
16051335
45.

[Experimental "functional amputate model" in ischemia-reperfusion].

Szokoly M, Németh N, Bráth E, Acs G, Hamar J, Mikó I, Furka I.

Magy Seb. 2005 Apr;58(2):138-43. Hungarian.

PMID:
16018284
46.

[Kidney neovascularization by the greater omentum after pretreatment with omental angiogenic factor].

Lesznyák T, Németh N, Bráth E, Peto K, Pekár G, Nagy D, Acs G, Dinya Z, Pap SJ, Mikó I, Furka I.

Magy Seb. 2005 Apr;58(2):129-33. Hungarian.

PMID:
16018282
47.

[Comparative hematologic and immunologic studies of patients with splenectomy and spleen autotransplantation].

Acs G, Furka I, Mikó I, Szendroi T, Hajdu Z, Sipka S Jr, Baráth S, Aleksza M, Csípo I, Baló E, Bálint A, Fekete K.

Magy Seb. 2005 Apr;58(2):74-9. Hungarian.

PMID:
16018271
48.

Erythropoietin signaling promotes invasiveness of human head and neck squamous cell carcinoma.

Mohyeldin A, Lu H, Dalgard C, Lai SY, Cohen N, Acs G, Verma A.

Neoplasia. 2005 May;7(5):537-43.

49.

Functional erythropoietin autocrine loop in melanoma.

Kumar SM, Acs G, Fang D, Herlyn M, Elder DE, Xu X.

Am J Pathol. 2005 Mar;166(3):823-30.

50.

Renal carcinomas with the t(6;11)(p21;q12): clinicopathologic features and demonstration of the specific alpha-TFEB gene fusion by immunohistochemistry, RT-PCR, and DNA PCR.

Argani P, Laé M, Hutchinson B, Reuter VE, Collins MH, Perentesis J, Tomaszewski JE, Brooks JS, Acs G, Bridge JA, Vargas SO, Davis IJ, Fisher DE, Ladanyi M.

Am J Surg Pathol. 2005 Feb;29(2):230-40.

PMID:
15644781

Supplemental Content

Support Center